This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Achillion Completes Enrollment in Rare Blood Disorder Study
by Zacks Equity Research
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
by Zacks Equity Research
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
by Zacks Equity Research
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
Achillion Reports Positive Interim Data on Factor D Inhibitors
by Zacks Equity Research
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
Why Is Achillion (ACHN) Up 4.7% Since Last Earnings Report?
by Zacks Equity Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Achillion (ACHN) Stock Options
by Zacks Equity Research
Achillion (ACHN) needs investors to pay close attention to the stock based on moves in the options market lately.
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
Why Is Achillion (ACHN) Up 24.7% Since Last Earnings Report?
by Zacks Equity Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Achillion Pharmaceuticals, Inc. (ACHN).
Achillion's 3rd Factor D Inhibitor Enters Clinical Studies
by Zacks Equity Research
Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.
RAD vs. WBA Which is a Better Stock Ahead of Earnings?
by Gourav Kanti Bagchi
Both Rite Aid and Walgreens Boots Alliance are scheduled to report earnings results on Jun 27 and Jun 28, respectively.
Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?
by Zacks Equity Research
Investors in Achillion Pharmaceuticals (ACHN) need to pay close attention to the stock based on moves in the options market lately.
Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares rise more than 15% on the day.
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Actinium Posts Positive DMC View on Lomab-B Phase III Trial
by Zacks Equity Research
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
by Zacks Equity Research
The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.
Insys' Cannabidiol Gets Fast Track Designation in the U.S.
by Zacks Equity Research
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.
by Zacks Equity Research
Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.
Alexion's (ALXN) Soliris Label Expansion Approved in Japan
by Zacks Equity Research
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA
by Zacks Equity Research
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.